KFDA approves GSK’s Paxil CR for use in PMDD and social anxiety disorder
Published: 2004-08-19 06:58:00
Updated: 2004-08-19 06:58:00
The Korea Food and Drug Administration said it has approved GSK’s Paxil (paroxetine HCl) controlled-release tablets for the treatment of premenstrual dysphoric disorder (PMDD) and social anxiety disorder in addition to initial indications, such as depression and panic disorder.
GSK officials ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
